3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
75
Colorectal Neoplasms
28
Breast Neoplasms
23
Esophageal Neoplasms
20
Pancreatic Neoplasms
13
Carcinoma, Non-Small-Cell Lung
11
Colonic Neoplasms
10
Rectal Neoplasms
9
Ovarian Neoplasms
8
Endometrial Neoplasms
8
Neoplasms
7
Neoplasm Metastasis
7
Gallbladder Neoplasms
7
Biliary Tract Neoplasms
7
Adenocarcinoma Of Esophagus
7
Urinary Bladder Neoplasms
6
Uterine Cervical Neoplasms
5
Prostatic Neoplasms
5
Lung Neoplasms
5
HER2-positive Gastric Cancer
5
Squamous Cell Carcinoma of Head and Neck
4
Cholangiocarcinoma
4
Carcinoma, Renal Cell
4
Carcinoma, Hepatocellular
4
Breast Neoplasms, Male
4
Adenocarcinoma
4
Thyroid Neoplasms
3
Salivary Gland Neoplasms
3
Bile Duct Neoplasms
3
Vulvar Neoplasms
2
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dihydropyrimidine Dehydrogenase Deficiency
×
Trastuzumab
×
Gastrointestinal
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled